ABVC BioPharm amends ophthalmology license deal to allow incremental milestone payments

ABVC BIOPHARMA, INC.

ABVC and BIOFIRST amended licensing agreement with ForSeeCon Eye Corp (FEYE) covering ophthalmology pipeline including Vitargus.
Second milestone payment of $3.5M can now be paid incrementally (e.g., $100k) at any time, rather than a single lump sum.
Amendment dated June 18, 2024; all other terms of the original March 25, 2024, license remain unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.